Drug Profile
ART 648
Alternative Names: ART-648; TAK-648Latest Information Update: 26 Jun 2023
Price :
$50
*
At a glance
- Originator Takeda
- Developer ARTham Therapeutics; Oita University; Takeda
- Class Antihyperglycaemics; Hepatoprotectants; Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bullous pemphigoid; Diabetic nephropathies; Non-alcoholic steatohepatitis
Most Recent Events
- 22 Jun 2023 Discontinued - Phase-I for Non-alcoholic steatohepatitis (In volunteers) in Japan (PO)
- 12 Apr 2023 Discontinued - Phase-II for Bullous pemphigoid in Japan (PO)
- 28 Jan 2022 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in Japan (PO)